blob

Mannkind (Mnkd.n) current price 6.3

Technosphere® Insulin System: MannKind’s lead investigational product candidate is currently in Phase 3 clinical trials in the U.S., Europe and Latin America, to study its safety and efficacy in the treatment of type 1 and type 2 diabetes. The therapy consists of a proprietary dry powder formulation of insulin that is inhaled into the deep lung using MedTone®, the company’s proprietary inhaler. Because the product has been found to produce a profile of insulin levels in the bloodstream that mimics the insulin profile normally seen in healthy individuals immediately following the beginning of the meal, researchers believe that the Technosphere® Insulin System may have the potential to change the way diabetes is treated. The potential use of insulin early in the progression of diabetes would represent a paradigm shift in the treatment of this disease and is currently be explored.

Il mercato potenziale è enorme

 Paris-based Sanofi wants a wider slice of the $14 billion
market for insulin products. Demand for the drugs is rising as
obesity and lack of exercise boost the number of people with
diabetes. The chronic disease, which can lead to organ damage,
affects 200 million people worldwide, and cases may double by
2025, according to the World Health Organization.

I players sul mercato sono Sanofi e Eli Lilly

Sanofi-Aventis SA's long-acting
insulin Lantus is easier to use than U.S. rival Eli Lilly & Co.'s
product Humalog in controlling blood-sugar levels, according to a
study sponsored by the French drugmaker.
     Both products have similar effectiveness. Patients preferred
glargine, or Lantus, which is injected once a day, rather than
shots three times a day with short-acting lispro, or Humalog,
said lead researcher Reinhard Bretzel from the Justus-Liebig
Universitaet in Giessen, Germany, in the study published in the
Lancet.
   ``We conclude that insulin glargine provides a simple and
effective option that is more satisfactory to patients than is
lispro for early initiation of insulin therapy, since it was
associated with a lower risk of hypoglycemia, fewer injections,
less blood glucose self monitoring, and greater patient
satisfaction, than was insulin lispro,'' Bretzel wrote.
     Lantus is a long-acting synthetic form of human insulin, the
hormone that controls sugar in the blood. Sanofi is trying to
show that Lantus may reduce some drawbacks associated with
conventional insulin preparations including weight gain and
hypoglycemia, an abnormal decrease of blood-sugar level.
     Sanofi rose 74 euro cents, or 1.6 percent, to 47.78 euros as
of 9:27 a.m. in Paris trading. The shares have declined 24
percent this year.